PC-SPES

Drug Profile

PC-SPES

Alternative Names: PC SPES

Latest Information Update: 30 Sep 2002

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator BotanicLab [CEASED]
  • Class Antineoplastics; Herbal medicines
  • Mechanism of Action Apoptosis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Prostate cancer

Most Recent Events

  • 28 Jun 2002 Discontinued - Phase-II for Prostate cancer in USA (PO)
  • 29 Aug 2001 A preclinical study has been added to the Cancer pharmacodynamics section
  • 07 Mar 2001 A retrospective study in prostate cancer has been added to the therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top